ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Liver-Specific Suppression of PLA2G6/iPLA
Kahori Shimizu, Mana Nishibata, Katsuyuki Nagata, Sho Hori, Shotaro Michinaga, Miyuki Kanehara, Miho Hashimoto-Iwasaki, Fuminori Sakurai, Hideo Shindou, Koji Tomita and 2 more
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Kahori ShimizuLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0003-1574-5526
Mana NishibataLaboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Katsuyuki NagataDepartment of Molecular Biology, The Jikei University School of Medicine, Tokyo, Japan.
Sho HoriLaboratory of Biochemistry and Molecular Biology, School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.
Shotaro MichinagaDepartment of Pharmacodynamics, Meiji Pharmaceutical University, Tokyo, Japan.
Miyuki KaneharaLaboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Miho Hashimoto-IwasakiLaboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Fuminori SakuraiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.
Hideo ShindouDepartment of Lipid Life Science, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3443-913X
Koji TomitaLaboratory of Molecular Biology, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Toru NishinakaLaboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Hiroyuki MizuguchiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0003-0594-8178
Funding
BOMU MELLNESS FOUNDATIONFoundation of Kinoshita Memorial EnterpriseJapan Agency for Medical Research and Development (AMED) 25fk0210150Japan Society for the Promotion of Science (JSPS) KAKENHI JP21K06680Japan Society for the Promotion of Science (JSPS) KAKENHI JP23H00552Japan Society for the Promotion of Science (JSPS) KAKENHI JP25K03046Mishima Kaiun Memorial FoundationNCGM Intramural Research Fund 21A2006NCGM Intramural Research Fund 22T001NCGM Intramural Research Fund 24A2011Osaka Ohtani University Research FoundationPlatform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED JP25ama121052Takara Bio Research Award
6 · The paper itself
Abstract
Phospholipase A2 group VI (PLA2G6, also called iPLA
Indexed as
Diet, High-FatGlucoseGroup VI Phospholipases A2Lipid MetabolismLiverAnimalsBlood GlucoseInsulinMaleMiceMice, Inbred C57BLPhospholipidsRNA, Small InterferingTriglyceridesBlood GlucoseGlucoseGroup VI Phospholipases A2InsulinPhospholipidsPla2g6 protein, mouseRNA, Small InterferingTriglyceridesadenovirus vectordiabetes mellitusmetabolic disordersmetabolic dysfunction‐associated steatotic liver diseasephospholipidsPLA2G6
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Liver-Specific Suppression of PLA2G6/iPLA · full record | OpenQuestion